TY - JOUR
T1 - Cimetidine decreases indomethacin induced duodenal mucosal damage in patients with acute musculoskeletal disorders
AU - Stalnikowicz, R.
AU - Pollak, D.
AU - Eliakim, A.
AU - Wengrower, D.
AU - Fich, A.
AU - Goldin, E.
AU - Ligumsky, M.
AU - Rachmilewitz, D.
PY - 1988
Y1 - 1988
N2 - The effect of two doses of cimetidine, 400 mg at night and 400 mg bd, on the protection of in domethacin (50 mg tid) induced mucosal damage was evaluated in a double blind study in patients with acute musculoskeletal disorders. Endoscopic mucosal lesions were scored before and after five to seven days of treatment. One hundred and ninety one patients were endoscoped before the trial, 34 (17·8%) had >one erosion and were not recruited. Forty patients were excluded for noncompliance, or lost to follow up. At the second endoscopy, oesophageal, and fundic damage was negligible. Gastric and duodenal lesion score in patients treated with cimetidine 400 mg bd: 2.7 (0·5) (SE); n=42) was significantly lower (p<0·0122) than in placebo treated patients: 6-1 (0·9) (n=50) or in patients treated with cimetidine 400 mg at night 7·1 (0·8) (n=21). Cimetidine 400 mg bd provided significant protection for the duodenum, but its protection of antral mucosa did not reach statistical significance. There was no correlation between upper gastrointestinal symptoms and endoscopic findings.
AB - The effect of two doses of cimetidine, 400 mg at night and 400 mg bd, on the protection of in domethacin (50 mg tid) induced mucosal damage was evaluated in a double blind study in patients with acute musculoskeletal disorders. Endoscopic mucosal lesions were scored before and after five to seven days of treatment. One hundred and ninety one patients were endoscoped before the trial, 34 (17·8%) had >one erosion and were not recruited. Forty patients were excluded for noncompliance, or lost to follow up. At the second endoscopy, oesophageal, and fundic damage was negligible. Gastric and duodenal lesion score in patients treated with cimetidine 400 mg bd: 2.7 (0·5) (SE); n=42) was significantly lower (p<0·0122) than in placebo treated patients: 6-1 (0·9) (n=50) or in patients treated with cimetidine 400 mg at night 7·1 (0·8) (n=21). Cimetidine 400 mg bd provided significant protection for the duodenum, but its protection of antral mucosa did not reach statistical significance. There was no correlation between upper gastrointestinal symptoms and endoscopic findings.
UR - http://www.scopus.com/inward/record.url?scp=0023768562&partnerID=8YFLogxK
U2 - 10.1136/gut.29.11.1578
DO - 10.1136/gut.29.11.1578
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 3061885
AN - SCOPUS:0023768562
SN - 0017-5749
VL - 29
SP - 1578
EP - 1582
JO - Gut
JF - Gut
IS - 11
ER -